June 3, 2019
The Ministry of Health, Labor and Welfare (MHLW) on May 30 granted orphan drug designation for three compounds including Bayer Yakuhin’s site-agnostic cancer drug larotrectinib and Novartis Pharma’s lung cancer treatment capmatinib. Larotrectinib, which Bayer licensed from Loxo Oncology, now...read more